MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2026.116833

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2026

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.

Nelson Axel, Alghaib Safa, Björkström Karl, Isaksson Karolin, Krabbe Ellen, Orme Sophie, Kadefors Måns, Wallander Mikael, Bjursten Sara, Ullenhag Gustav J, Carneiro Ana, Helgadottir Hildur, Ny Lars, Olofsson Bagge Roger

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Circadian rhythms regulate immune cell trafficking and function, and emerging clinical data suggest that the timing of immune checkpoint inhibitor (ICI) administration may influence efficacy. In advanced disease, later-day administration has been associated with inferior outcomes. Whether this applies to neoadjuvant ICI in resectable stage III-IV melanoma is unknown.

METHODS

This retrospective cohort study included patients with resectable stage III-IV cutaneous melanoma treated with neoadjuvant ICI at four Swedish academic centers. Patients were categorized by timing of ICI across two infusions (morning, both <12:00; afternoon, both ≥12:00; mixed, one <12:00 and one ≥12:00). The primary endpoint was major pathological response. Secondary endpoints were event-free (EFS), distant metastasis-free (DMFS), melanoma-specific (MSS), and overall survival (OS). Associations were assessed using logistic regression and Cox models.

RESULTS

A total of 265 patients were included (morning, n = 94; mixed, n = 96; afternoon, n = 75). Major pathological response rates were similar across groups (morning 47%, mixed 44%, afternoon 40%; p = 0.68). After a median follow-up of 17.4 months, morning administration was associated with a lower hazard of events across survival endpoints versus afternoon, including DMFS (HR 0.47, 95% CI 0.23-0.96), MSS (HR 0.18, 95% CI 0.04-0.71), and OS (HR 0.13, 95% CI 0.04-0.50) but not EFS (HR 0.58, 95% CI 0.31-1.08), compared with afternoon administration. Associations remained after adjustment for pathological response.

CONCLUSIONS

Time of day of neoadjuvant ICI administration was not associated with pathological response. However, afternoon administration was associated with worse survival outcomes. These findings suggest treatment timing may influence long-term outcomes, although prospective validation is needed.

Для цитирования: Nelson Axel, Alghaib Safa, Björkström Karl, Isaksson Karolin, Krabbe Ellen, Orme Sophie, Kadefors Måns, Wallander Mikael, Bjursten Sara, Ullenhag Gustav J, Carneiro Ana, Helgadottir Hildur, Ny Lars, Olofsson Bagge Roger. Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.. European journal of cancer (Oxford, England : 1990). 2026. DOI: 10.1016/j.ejca.2026.116833.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.